FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2708-2710 June 24, 2004 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lange, H. PubMed Citation

Cardiologists agree that the best and safest percutaneous coronary intervention is the one that never becomes necessary. In this regard, new therapies that prevent restenosis and retard or reverse atherosclerosis are welcomed by noninvasive and interventional cardiologists alike. However, clinically important coronary stenoses and acute coronary syndromes will develop in many patients despite our best efforts at prevention. In such cases, interventionalists may fix the culprit lesion mechanically, but treatment should not end when patients leave the catheterization laboratory (Figure 1).

View larger version (64K): [in this window] [in a new window]   Figure 1. Cutaway View of a Coronary Artery Showing a Stent Implanted to Treat a Previously Flow-Limiting Stenosis. The . . . [Full Text of this Article]

 

Source Information

From the University of Pennsylvania, Philadelphia.

This article has been cited by other articles:

• Stanger, O., Fowler, B., Herrmann, W., Lange, H., Suryapranata, H. (2004). Folate Therapy and In-Stent Restenosis. NEJM 351: 1259-1260 [Full Text]